In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Peptides are surging in popularity. There's little evidence that they work. The Widmark Formula and Calculating Your BAC Level Gambone Law As unregulated peptides grow in popularity, doctors warn of unknown risks ABC7 San Francisco